These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

651 related items for PubMed ID: 16771848

  • 1. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
    Flavell DJ, Warnes SL, Bryson CJ, Field SA, Noss AL, Packham G, Flavell SU.
    Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
    [Abstract] [Full Text] [Related]

  • 2. Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia.
    Flavell DJ, Warnes S, Noss A, Flavell SU.
    Cancer Res; 1998 Dec 15; 58(24):5787-94. PubMed ID: 9865737
    [Abstract] [Full Text] [Related]

  • 3. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
    Flavell DJ, Boehm DA, Noss A, Warnes SL, Flavell SU.
    Br J Cancer; 2001 Feb 15; 84(4):571-8. PubMed ID: 11207056
    [Abstract] [Full Text] [Related]

  • 4. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.
    Flavell DJ, Warnes SL, Noss AL, Flavell SU.
    Br J Cancer; 2000 Dec 15; 83(12):1755-61. PubMed ID: 11104577
    [Abstract] [Full Text] [Related]

  • 5. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.
    Flavell DJ, Flavell SU, Boehm DA, Emery L, Noss A, Ling NR, Richardson PR, Hardie D, Wright DH.
    Br J Cancer; 1995 Dec 15; 72(6):1373-9. PubMed ID: 8519647
    [Abstract] [Full Text] [Related]

  • 6. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E.
    Haematologica; 2002 Jan 15; 87(1):33-43. PubMed ID: 11801463
    [Abstract] [Full Text] [Related]

  • 7. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
    Thorpe PE, Brown AN, Bremner JA, Foxwell BM, Stirpe F.
    J Natl Cancer Inst; 1985 Jul 15; 75(1):151-9. PubMed ID: 3859688
    [Abstract] [Full Text] [Related]

  • 8. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [Abstract] [Full Text] [Related]

  • 9. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
    Bonardi MA, French RR, Amlot P, Gromo G, Modena D, Glennie MJ.
    Cancer Res; 1993 Jul 01; 53(13):3015-21. PubMed ID: 7686448
    [Abstract] [Full Text] [Related]

  • 10. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines.
    Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S.
    Leuk Res; 2006 May 01; 30(5):625-31. PubMed ID: 16289746
    [Abstract] [Full Text] [Related]

  • 11. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
    Lopes de Menezes DE, Denis-Mize K, Tang Y, Ye H, Kunich JC, Garrett EN, Peng J, Cousens LS, Gelb AB, Heise C, Wilson SE, Jallal B, Aukerman SL.
    J Immunother; 2007 Jan 01; 30(1):64-74. PubMed ID: 17198084
    [Abstract] [Full Text] [Related]

  • 12. CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab.
    Dijoseph JF, Dougher MM, Armellino DC, Kalyandrug L, Kunz A, Boghaert ER, Hamann PR, Damle NK.
    Cancer Immunol Immunother; 2007 Jul 01; 56(7):1107-17. PubMed ID: 17160682
    [Abstract] [Full Text] [Related]

  • 13. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone.
    Flavell DJ, Boehm DA, Emery L, Noss A, Ramsay A, Flavell SU.
    Int J Cancer; 1995 Jul 28; 62(3):337-44. PubMed ID: 7543082
    [Abstract] [Full Text] [Related]

  • 14. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
    Lopes de Menezes DE, Pilarski LM, Allen TM.
    Cancer Res; 1998 Aug 01; 58(15):3320-30. PubMed ID: 9699662
    [Abstract] [Full Text] [Related]

  • 15. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
    Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC.
    J Immunother; 2001 Aug 01; 24(3):263-71. PubMed ID: 11394505
    [Abstract] [Full Text] [Related]

  • 16. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
    DiJoseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR, Moran JK, Damle NK.
    Clin Cancer Res; 2006 Jan 01; 12(1):242-9. PubMed ID: 16397048
    [Abstract] [Full Text] [Related]

  • 17. Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma.
    Glennie MJ, Brennand DM, Bryden F, McBride HM, Stirpe F, Worth AT, Stevenson GT.
    J Immunol; 1988 Nov 15; 141(10):3662-70. PubMed ID: 3141503
    [Abstract] [Full Text] [Related]

  • 18. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
    Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, Bebbington C, Yarranton G.
    Cancer Immunol Immunother; 2002 Mar 15; 51(1):15-24. PubMed ID: 11845256
    [Abstract] [Full Text] [Related]

  • 19. A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2Rγ(null) mouse lymphoma model.
    Sato F, Ito A, Ishida T, Mori F, Takino H, Inagaki A, Ri M, Kusumoto S, Komatsu H, Iida S, Okada N, Inagaki H, Ueda R.
    Cancer Immunol Immunother; 2010 Dec 15; 59(12):1791-800. PubMed ID: 20714721
    [Abstract] [Full Text] [Related]

  • 20. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
    Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4556-64. PubMed ID: 17671142
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.